{"id":"cgrp-mabs-and-onabotulinumtoxin-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Muscle weakness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Neck pain"},{"rate":null,"effect":"Antibody formation (CGRP mAbs)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CGRP mAbs bind to CGRP or its receptor to prevent neuropeptide-mediated vasodilation and neurogenic inflammation implicated in migraine pathogenesis. OnabotulinumtoxinA blocks acetylcholine release at motor endplates, reducing muscle tension and potentially modulating pain signaling in chronic migraine. The combination targets complementary pathways in migraine biology.","oneSentence":"This combination blocks calcitonin gene-related peptide (CGRP) signaling via monoclonal antibodies while simultaneously inhibiting acetylcholine release at the neuromuscular junction via onabotulinumtoxin A to reduce migraine frequency and severity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:26.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic migraine (phase 3 combination study)"}]},"trialDetails":[{"nctId":"NCT07040813","phase":"PHASE3","title":"The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-06-06","conditions":"Migraine, Chronic Migraine Headache","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CGRP mAbs and onabotulinumtoxin A","genericName":"CGRP mAbs and onabotulinumtoxin A","companyName":"Oslo University Hospital","companyId":"oslo-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks calcitonin gene-related peptide (CGRP) signaling via monoclonal antibodies while simultaneously inhibiting acetylcholine release at the neuromuscular junction via onabotulinumtoxin A to reduce migraine frequency and severity. Used for Chronic migraine (phase 3 combination study).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}